Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.
Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.
Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.
Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.
Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of
Amgen announced groundbreaking results from the Phase 3 E1910 trial, demonstrating that BLINCYTO combined with chemotherapy significantly improves survival for adults with Philadelphia chromosome-negative B-ALL. At 3.5 years, survival rates were 83% for those receiving BLINCYTO plus chemotherapy, compared to 65% for chemotherapy alone. The study, conducted by the ECOG-ACRIN Cancer Research Group, showed a 58% reduction in death risk with BLINCYTO. These findings will be submitted to regulatory authorities. No new safety concerns were noted, reinforcing BLINCYTO's efficacy in treating this challenging cancer.
Amgen (NASDAQ:AMGN) declared a $2.13 per share dividend for Q1 2023, reflecting a 10% increase from previous quarters. The dividend payment date is set for March 8, 2023, with record holders as of February 15, 2023. This positive adjustment demonstrates Amgen's commitment to returning value to shareholders amidst its ongoing developments in innovative therapeutics. The company continues to focus on high unmet medical needs while advancing its production capabilities and product pipeline.
Amgen (NASDAQ:AMGN) announced a webcast for the investment community at 8:00 a.m. ET on December 12, 2022, following its acquisition of Horizon Therapeutics. CEO Robert A. Bradway and the executive team will participate in the call, which will be accessible to media and the public. The event will be archived for 90 days on Amgen’s website. This acquisition highlights Amgen's commitment to addressing serious medical needs and expanding its innovative pipeline of therapeutics.
Amgen has announced a recommended cash offer for Horizon Therapeutics PLC, with Pillartree Limited, a subsidiary wholly owned by Amgen, acquiring Horizon's entire share capital at $116.50 per share. This represents a premium of approximately 47.9% over Horizon's November 29 closing price. The total transaction values Horizon at $27.8 billion, with an enterprise value of $28.3 billion. Amgen plans to finance this acquisition through a $28.5 billion bridge credit agreement, enhancing its portfolio in inflammation and nephrology, and is expected to drive revenue growth starting in 2024.
Amgen announced encouraging Phase 1 results for AMG 133, a novel bispecific molecule targeting obesity. The study reported a weight reduction of up to 14.5% at the highest dose (420mg Q4W) over 12 weeks. Most treatment-related adverse events were mild, primarily gastrointestinal. Based on the promising safety and efficacy results, Amgen is set to initiate a Phase 2 study in early 2023 to explore long-term effects. Overweight and obesity are significant global health issues, complicating patient health and healthcare systems.
Amgen will host a webcast call for investors at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease on Dec. 5, 2022, at 8:00 a.m. ET. David M. Reese, M.D., will present Phase 1 data on AMG 133, a novel bispecific receptor targeting GIPR and GLP-1. The webcast will be publicly accessible and archived for 90 days post-event.
Amgen, a leader in innovative human therapeutics, aims to address high unmet medical needs and has a robust pipeline. For more details, visit www.amgen.com.
Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference on November 29, 2022, at 11:20 a.m. ET. David M. Reese, M.D., executive vice president of Research and Development, will lead the presentation. The event will be web-streamed and accessible to media, investors, and the public, with archives available for 90 days on Amgen's website. The company focuses on innovative therapeutics for serious health issues, leveraging advanced genetics. Amgen is a leading biotechnology company, featured in the Dow Jones Industrial Average and Nasdaq-100 index.
Amgen presented new analysis data from the Phase 3 FOURIER and FOURIER-OLE studies of Repatha (evolocumab) at the AHA Scientific Sessions 2022. Results indicate that maintaining LDL-C levels below 20 mg/dL correlates with improved cardiovascular outcomes, without new safety signals over up to 8.6 years of follow-up. Notably, 13% of patients achieved these low LDL-C levels, leading to a decreased risk of cardiovascular events like myocardial infarction and stroke. The data supports the role of Repatha in managing atherosclerotic cardiovascular disease (ASCVD) risk.
Amgen (NASDAQ:AMGN) announced new clinical data highlighting the effectiveness of AMGEVITA® (adalimumab) and TAVNEOS® (avacopan) at the upcoming American College of Rheumatology Convergence from Nov. 10-14, 2022. The data will present real-world evidence on treatment satisfaction and persistence of AMGEVITA among German patients with rheumatic diseases. Additionally, TAVNEOS research will focus on renal function recovery in severe active ANCA-associated vasculitis patients. This research showcases Amgen's commitment to innovation in treating inflammatory diseases.
Amgen announced phase 2 clinical trial results for olpasiran, showing over 95% reduction in lipoprotein(a) levels in patients with atherosclerotic cardiovascular disease (ASCVD). Conducted with 281 participants, the trial demonstrated significant efficacy at doses of 75 mg and higher every 12 weeks. Results were shared at the American Heart Association meeting and published in the New England Journal of Medicine. Amgen plans to start a phase 3 trial in December 2022 to further explore olpasiran's potential.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
